Contrasting Azenta (NASDAQ:AZTA) & Danaher (NYSE:DHR)

Danaher (NYSE:DHR – Get Free Report) and Azenta (NASDAQ:AZTA – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Danaher and Azenta”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Danaher $24.57 billion 6.31 $3.61 billion $6.11 36.08
Azenta $621.70 million 3.15 -$166.99 million ($3.62) -12.35

Danaher has higher revenue and earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

79.0% of Danaher shares are owned by institutional investors. Comparatively, 99.1% of Azenta shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Comparatively, 10.9% of Azenta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Danaher has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Azenta has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Danaher and Azenta, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Danaher 0 5 18 0 2.78
Azenta 1 2 4 0 2.43

Danaher presently has a consensus price target of $242.91, suggesting a potential upside of 10.20%. Azenta has a consensus price target of $47.60, suggesting a potential upside of 6.49%. Given Danaher’s stronger consensus rating and higher probable upside, equities analysts plainly believe Danaher is more favorable than Azenta.

Profitability

This table compares Danaher and Azenta’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Danaher 16.91% 11.17% 6.71%
Azenta -26.86% 1.41% 1.15%

Summary

Danaher beats Azenta on 11 of the 14 factors compared between the two stocks.

About Danaher

(Get Free Report)

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.

About Azenta

(Get Free Report)

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.